NanoViricides Inc. (NNVC)

[DaysOnTheBeach]

Referenced in today's PR -- NNVC FluCide's EXCELLENT Pre-Clinical Results Recap!

Lest we forget in the swill of all the opposing points of view, here are snippets from a recent PR which detailed a presentation by company president Diwan to an Influenza Conference earlier in the month. His presentation recapped the EXCELLENT animal trial results from previous studies which form the basis for the push toward human trials for FluCide. THIS is the science. In my opinion THIS is why this company will succeed and why share price will eventually explode.

http://finance.yahoo.com/news/nanoviricides-president-dr-diwan-presented-120000451.html


ALL of the FluCide treated animals survived, while NONE of the non-treated animals survived:

Dr. Diwan discussed the nanoviricides® technology platform, and presented the pre-clinical data on the Company’s first drug candidate, NV-INF-1, Injectable FluCide™, to treat all influenza infections in hospitalized patients. Influenza A H1N1 infected animals treated with FluCide survived the full 21-day observation period, whereas animals treated with 40mg/kg/d oseltamivir phosphate (Tamiflu®) survived only 8 days in this highly lethal study. Influenza A/WS/33/ (H1N1) virus was used in this study. The highly lethal infectious dose of 1M viral particles at time 0 h followed by another 1M virus particles at 23h that was employed caused uniform lethality in 5 days in untreated mice. Body weight began to decline in the infected, untreated mice, by days 2-3 days and continued to decline until death. The Oseltamivir-treated mice maintained body weight only through day 5, which declined thereafter until death. Similar to the survival results, the mice treated with NV-INF-1 maintained their body weight substantially longer, through day 14. NV-INF-1 demonstrated an unparalleled 1,000-fold reduction in lung viral load compared to untreated animals on day 4 in this lethal animal model study.


The pre-clinical safety profile for FluCide is extraordinary, essentially perfect:

Dr. Diwan also discussed the extremely high safety of NV-INF-1 observed in preliminary safety/toxicology studies. He noted that no significant changes in all observed parameters were found even at the maximum feasible dose of approximately 2,700 mg/kg/d repeatedly given for five consecutive days.


The potential market for the company's combined portfolio of drugs once through FDA approval in the coming years is HUGE:

The total market size addressed by the Company’s current drug programs is estimated at about $50 billion. In addition to Injectable FluCide, the Company is working on five more commercially important drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a broad-spectrum antiviral drug for viral diseases of the external eye. All of our programs are for therapeutics to treat viral infections. Our drugs are expected to be useful as prophylactics as well. DengueCide has recently received orphan drug designation by the US FDA as well as the European EMA.

-----

The company market cap is currently around $220M. If all drugs succeed through approval in the coming years (not guaranteed), picking a conservative multiplier of five times annual sales, on the high end the company could potentially be valued as high as $250B, for a one thousand times share price appreciation. In that best case scenario, share price under the current post-split structure could be north of $4,000 per share. Or under far more conservative assumptions, maybe share price appreciates only one forth that magnitude, to "only" $1,000 a share? Even reduce that by another factor of four... maybe "only" $250 a share?


Best to all.